Delinia Alternatives & Competitors

12 companies similar to Delinia — Pioneering breakthrough treatments for autoimmune and inflammatory diseases with...

Nuvig Therapeutics Inc.

Rebalancing Immune Function for Chronic Inflammatory and Autoimmune Diseases

24 Series A $47.00M

Menlo Park, United States

Biotechnology Health Care +1

Georgiamune Inc.

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fi...

30 Series A $75.00M

Gaithersburg, United Stat...

Biotechnology Health Care +1

Q32 Bio Inc.

Revolutionizing the future of targeted immune therapeutics

28 $255.50M

Waltham, United States

Biotechnology Health Care +1

Compare

Egle Therapeutics

Modulating T-regulatory cells to balance immunity

45 Grant $49.30M

Paris, France

Biotechnology Health Care +1

Compare

Rival Readout

Competing with Delinia? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout

AnaptysBio

Transforming patient health by delivering innovative immunology therapeutics.

144 IPO $185.90M

San Diego, United States

Biotechnology Health Care +1

Promedior

Pioneering advanced therapies to heal fibrotic and inflammatory diseases at their source,...

Venture round $63.00M

Biopharma Biotechnology +2

Enlivex Therapeutics (Nasdaq: ENLV)

Immune rebalancing

41 Post-IPO Equity

Israel

Biotechnology Health Care +1

Abcuro, Inc

Developing immunotherapies for autoimmune diseases and cancer

43 Series B $214.85M

Biotechnology Health Care +1

Asylia Therapeutics

Innovative therapies reshaping immune responses against autoimmune, cancer, and infectious...

1 Series A $14.50M

Biotechnology Health Care +1

ImCheck Therapeutics

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic

57 Grant $193.11M

Marseille, France

Biopharma Biotechnology +3

Siolta Therapeutics

16 Series C $42.00M

San Carlos, United States

Biotechnology Health and Wellness

VBL Therapeutics (Nasdaq:VBLT)

Engineering the future of targeted medicines, breaking barriers to develop the next genera...

15 Post-IPO Equity $62.76M

Israel

Biotechnology Health Care +1

About Delinia

Delinia is a biotechnology company at the forefront of developing innovative treatments for autoimmune and inflammatory diseases. Founded in 2015 and headquartered in the United States, the company focuses on enhancing Regulatory T Cells (Tregs) to maintain immune system balance. These powerful immune cells are essenti...

Business keywords

Autoimmune Disease Treatment, Inflammatory Disease Therapies, Regulatory T Cells, Tregs Expansion, Immune System Homeostasis, Novel Therapeutics, Self-tolerance Maintenance, Immune System Balance, Molecule Development, Autoimmune Pathophysiology, Therapeutic Innovation, Clinical Advancements, Immune Regulatory Cells, Scientific Discovery

Frequently Asked Questions

Companies similar to Delinia include Nuvig Therapeutics Inc., Georgiamune Inc., Q32 Bio Inc., Egle Therapeutics, AnaptysBio. They work in Biotechnology and Health and Wellness and share Delinia's focus on scientific discovery and novel therapeutics.

Bounce Watch lists 12 companies that share Delinia's industries and are closest to it in business tags, services, target customers, business model and size.

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around Delinia: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Book a 7-day Readout Get a free snapshot

Explore Related

Delinia Profile Nuvig Therapeutics Inc. Alternatives Georgiamune Inc. Alternatives Q32 Bio Inc. Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Delinia on 30 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.